Clarivate Plc

Clarivate Plc engages in the provision of global information, analytics and workflow solutions. It operates through the Science and Intellectual Property segments. The Science segment is composed of the academia and government, and life science and healthcare product lines. The Intellectual Property segment includes the patent, trademark, domain, and IP management product lines. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clarivate Plc reports strong Q4 earnings, eyes growth opportunities

Clarivate Plc delivered strong financial results in Q4 2022, driven by the successful ProQuest acquisition and solid organic growth across segments. The company is focused on achieving higher organic growth, reducing leverage, and leveraging culture for success.
While facing macroeconomic challenges and pricing pressures, Clarivate Plc is confident in its strategic plans and capital structure initiatives. Opportunities lie in leveraging AI, enhancing product offerings, and capitalizing on the positive pricing environment.
Navigating challenges such as tough comps, managing inflation impact, and balancing quarterly patterns will be crucial. The company's proactive approach to growth, focus on customer value, and upcoming Investor Day position it well for future success.

Clarivate Plc reports stable Q1 performance amidst growth challenges

Clarivate Plc's Q1 2023 performance showcased stable revenue, strong margins, and strategic financial initiatives despite challenges in net income and organic growth cadence.
The company's strengths lie in market engagement, AI innovation, maintained outlook, and effective pricing strategies, positioning it for continued growth.
Challenges include earnings volatility, execution hurdles in growth projections, and longer-term segment revenue impacts, necessitating strategic planning and operational focus.
Opportunities in AI applications, cash flow utilization, revenue drivers, and segment progress offer avenues for revenue diversification, growth investments, and market expansion.

Clarivate Plc faces revenue challenges but drives growth through innovation

Clarivate Plc's Q2 performance saw challenges in key segments impacting revenue and outlook, despite operational improvements and strategic initiatives.
While facing hurdles in patent annuities and commercialization subsegment growth, the company focuses on sustainability, product innovations, and customer-centric strategies for future growth.
Detailed financial results and revised guidance reflect the company's proactive approach to address challenges and capitalize on opportunities for sustainable growth.
With a pivot around three segments and emphasis on higher-touch sales, Clarivate aims to navigate challenges, leverage opportunities, and drive revenue growth in the evolving market landscape.

Clarivate Plc reports Q3 growth, tackles challenges, eyes tech acquisitions

Clarivate Plc's Q3 performance showed growth in key segments despite challenges in IP and LS&H businesses.
Opportunities lie in technology acquisitions, analytic platforms, and direct sales to pharma companies.
Management remains optimistic about quarterly results and progress, focusing on enhancing growth strategies.

Clarivate Plc reports solid Q4 performance amidst sector challenges

Clarivate Plc's Q4 2023 performance reflects progress in key segments and a strategic focus on organic growth and operational efficiencies.
While facing challenges in the A&G segment and market conservatism, the company is leveraging strengths in Life Sciences investments and pricing strategies.
Opportunities lie in growth acceleration through new offerings, improved organic growth, and renewed optimism in the life sciences sector.

Clarivate Plc reports Q1 revenue growth, eyes segment expansion

Clarivate Plc's Q1 performance showed promising organic revenue growth and steady renewal rates, with a focus on future investments for growth.
While facing financial challenges and neutral market conditions, the company sees opportunities in segment growth and real-world data solutions.
Overall, Clarivate remains on track with full-year guidance, aiming for 1% organic growth and focusing on driving subscription business growth.

Clarivate Plc reports mixed Q2 results, focuses on growth strategies

Clarivate Plc reported mixed financial results in Q2 2024, with slight revenue growth but challenges in certain segments.
Management emphasized resilience in adjusted EPS and operating cash flow, focusing on growth plans and operational improvements.
Analysts raised concerns about project delays and segment performance, but opportunities in product innovation and revenue growth were highlighted.
The company aims to drive subscription revenue growth through upcoming product releases and investment in business.

Clarivate Plc faces revenue decline in Q3 but focuses on growth strategies

Clarivate Plc's Q3 2024 earnings call highlighted challenges in revenue decline and net loss, with a focus on repositioning and value creation. The company is implementing a Value Creation Plan to optimize its business model and drive sustainable growth. Opportunities exist in improving sales execution, product innovation, and aligning the portfolio for enhanced profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clarivate Plc engages in the provision of global information, analytics, and workflow solutions. It operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H). The A&G segment involves the provision of research and analytics, content aggregation, and workflow software solutions using artificial intelligence. The IP segment includes the maintenance, intelligence, and management solutions. The LS&H focuses on solutions for research and development, regulatory and safety, and commercialization. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Acquisition of MotionHall reinforces strategy to lead market-specific solutions, including workflows and expert services fuelled by industry vertical AI LONDON , March 21, 2024 /PRNewswire/ --  Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, has announced an agreement to acquire the substantial majority of assets of MotionHall, a Silicon Valley technology start-up company serving the life sciences with industry vertical artificial intelligence (AI) solutions. The asset purchase serves as a key component of the Clarivate™ Life Sciences & Healthcare strategy to deliver transformative intelligence through the application of generative AI (GenAI) and proprietary industry vertical AI solutions.

Clarivate Acquires AI Start Up to Accelerate Strategy and Business Development Success for Life Sciences & Healthcare Clients

--- Gordon Samson, President, Intellectual Property, Provides a Virtual Update on Strategy and Generative AI Initiatives --- LONDON , March 20, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today the launch of the third and final video in a series of Clarivate in the Age of AI webinar presentations led by the Presidents of its three segments: Academia & Government, Life Sciences & Healthcare and Intellectual Property.  The Intellectual Property (IP) video presentation highlights how Clarivate plays an important role in the IP ecosystem by serving as an indispensable partner to more than 20,000 customers.

New Webinar: Clarivate in the Age of AI - Driving Innovation in Intellectual Property Management and Decision Making

Clarivate PLC's 4Q23 performance disappointed investors due to a weak macrocycle, but certain parts of the business are improving. Subscription and recurring revenue growth are accelerating, comprising a significant portion of the business. Management is implementing strategies to drive organic growth, including product portfolio restructuring and a shift in the LS&H segment.

Clarivate PLC: Agree Q4'23 Was Weak, But The Upside Remains Attractive

--- Henry Levy, President, Life Sciences & Healthcare, Provides a Virtual Update on Strategy and Generative AI Initiatives --- LONDON , March 13, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today the launch of the second video in a series of Clarivate in the Age of AI webinar presentations led by the Presidents of its three segments: Academia & Government, Intellectual Property and Life Sciences & Healthcare. The Life Sciences & Healthcare video presentation highlights how Clarivate serves as an indispensable partner to our customers by providing solutions that enable mission critical decision making across the enterprise and the drug and medical device lifecycle.

New Webinar: Clarivate in the Age of AI - Empowering Our Life Sciences & Healthcare Customers to Create a Healthier Tomorrow

LONDON , March 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Jonathan Collins, Executive Vice President and Chief Financial Officer, and Henry Levy, President, Life Sciences & Healthcare, will present at the BofA Securities 2024 Information & Business Services Conference on Thursday, March 14, 2024 at 3:35 pm Eastern Time. The live webcast can be accessed at https://bofa.veracast.com/webcasts/bofa/infoservices2024/id8q5vjH.cfm and will be available for replay.

Clarivate to Present at the BofA Securities 2024 Information & Business Services Conference on March 14

--- Bar Veinstein, President, Academia & Government, Provides a Virtual Update on Strategy and Generative AI Initiatives --- LONDON , March 6, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today the launch of the first in a series of Clarivate in the Age of AI video webinar presentations led by the Presidents of its three segments: Academia & Government, Intellectual Property and Life Sciences & Healthcare.  The Academia & Government video presentation highlights how Clarivate serves as an indispensable partner to our customers by providing mission critical solutions, which are embedded in customers workflows, powered by trusted, curated scholarly content.

New Webinar: Clarivate in the Age of AI - Innovation Rooted in Academia

New report introduces rankings for the first time; Samsung Electronics leads the list LONDON , March 5, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today revealed its 2024 list of Top 100 Global Innovators™ – organizations leading the world in technology research and innovation. For the first time, Clarivate ranked the top 100 organizations to provide a more defined view, as competition for exceptional patentable ideas grows more intense.

Clarivate Reveals Top 100 Global Innovators 2024

Exor becomes a long-term investor in Clarivate, endorsing the strategic direction set out by the Company's Management and Board, and announces it now has a 10.1% shareholding in the Company and can increase its participation up to 17.5% LONDON and AMSTERDAM , March 4, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence and Exor N.V. (AEX: EXO), the Netherlands-based diversified holding company, today announced that Suzanne Heywood will be nominated for election to the Clarivate Board of Directors at the Company's next Annual General Meeting of shareholders on May 7, 2024.

Clarivate and Exor Sign Agreement Under Which Suzanne Heywood Will Be Nominated to Stand for Election to the Company's Board of Directors

Clarivate and Exor sign agreement

Clarivate Plc (CLVT) Q4 2023 Earnings Call Transcript

The headline numbers for Clarivate PLC (CLVT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Clarivate PLC (CLVT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

— Provides 2024 Outlook — LONDON , Feb. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the fourth quarter and full year ended December 31, 2023. Fourth  Quarter 2023 Financial Highlights Revenues of $683.7 million increased 1.2%, and decreased 0.6% at constant currency(2) Organic revenues increased 0.1% as increases in subscription revenues of 2.6% and re-occurring revenues of 3.8% were offset by a decline in transactional and other revenues of 8.3% Net loss attributable to ordinary shares of $863.0 million due to the $844.7 non-cash impairment of goodwill and intangible assets; Net loss per diluted share of $1.30 Adjusted net income(1) of $163.4 million decreased 0.4%; Adjusted diluted EPS(1) of $0.23 increased 4.5% or $0.01 Adjusted EBITDA(1) of $298.2 million decreased 2.0%; Adjusted EBITDA Margin(1) of 43.6% decreased 150 basis points Net cash provided by operating activities increased $54.0 million to $190.9 million; Free cash flow(1) increased $36.5 million to $127.0 million Full Year 2023 Financial Highlights Revenues of $2,628.8 million decreased 1.2%, and 2.1% at constant currency(2), driven primarily by the divestiture of MarkMonitor in October 2022, for which there were no comparable amounts in the current year period Organic revenues increased 0.3% as increases in subscription revenues of 2.4% and re-occurring revenues of 0.2% were offset by a decline in transactional and other revenues of 5.4% Net loss attributable to ordinary shares of $986.6 million improved from a loss of $4,035.6 million for the full year 2022 due to a $3,469.2 million reduction of non-cash impairment charges of goodwill and intangible assets; Net loss per diluted share of $1.47 improved by $4.77 Adjusted net income(1) of $599.1 million decreased 4.6%; Adjusted diluted EPS(1) of $0.82 decreased 3.5% or $0.03 Adjusted EBITDA(1) of $1,117.2 million increased 0.4% and Adjusted EBITDA Margin(1) of 42.5% increased 70 basis points Net cash provided by operating activities increased $234.9 million to $744.2 million; Free cash flow(1) increased $195.3 million to $501.7 million "In 2023, we delivered subscription revenue growth and navigated through market headwinds.

Clarivate Reports Fourth Quarter and Full Year 2023 Results

Highly recommended in trademark management, searching and watching, renewals and recordals LONDON , Feb. 23, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, has been recognized in the WTR 1000 2024 by the World Trademark Review. This guide identifies the top trademark professionals and firms in over 80 jurisdictions around the globe.

Clarivate Recognized in the WTR 1000 2024 for Trademark Business

Evaluate the expected performance of Clarivate PLC (CLVT) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Countdown to Clarivate PLC (CLVT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

Bringing together expertise, operational practice knowledge and powerful data models to improve innovation and IP decision-making LONDON , Feb. 20, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today launched the Clarivate Center for IP and Innovation Research™, a new expert unit which will guide corporations and research organizations in their mission to create innovative ideas, valuable technology and brand IP assets. The Center will combine more than 60 years of intellectual property management and data-creation with analysis experience from Clarivate, pioneering high-performance benchmarks and practice.

Clarivate Launches New Center for Intellectual Property and Innovation Research

LONDON , Feb. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global provider of transformative intelligence, has partnered with the Financial Times (FT) for the sixth consecutive year to provide it with trusted high-quality data for three of its business school rankings, including the Global MBA Rankings launched today. The FT is one of the world's leading business news organizations, recognized internationally for its authority, integrity and accuracy.

Clarivate Partners with the Financial Times to Power its Business School Rankings

LONDON , Feb. 1, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced today that it has successfully completed the refinancing of its term loan B credit facility and the extension of the maturity date of its revolving credit facility. Pursuant to an amendment to the Company's existing credit agreement dated as of October 31, 2019, the Company refinanced all of its existing term loans with a new $2.150 billion tranche of term loans maturing in 2031, with a reduced interest rate margin of 275 basis points per annum in the case of loans bearing interest by reference to term SOFR.

Clarivate Completes Refinancing of Term Loan and Revolver Extension

New solution integrates  curated data from Pivot-RP to the Web of Science  and offers  a n expanded view of the funding landscape LONDON , Jan. 29, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today launched the Web of Science™ Grants Index. The new solution is designed to provide a more comprehensive, enriched view of the funding landscape, empowering researchers to make confident, informed decisions when they seek research funding.

Clarivate Launches Web of Science Grants Index to Help Researchers Optimize Funding Strategies

LONDON , Jan. 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced today it will report its financial results for the fourth quarter and full year 2023 before the market opens on Tuesday, February 27. The press release and earnings supplement, with accompanying financial information, will be posted on the Clarivate investor website.

Clarivate to Report Fourth Quarter and Full Year 2023 Results on February 27, 2024

LONDON , Jan. 22, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced today the launch of a process to refinance the Company's 2026 Term Loan B credit facility that would extend the maturity to 2031 for a new combined term loan amount of $2.2 billion. "We are proactively capitalizing on the favorable debt market environment in order to provide further flexibility within our capital structure," said Jonathan Collins, Executive Vice President and Chief Financial Officer.

Clarivate Announces Commencement of Term Loan Refinancing Transaction

Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies LONDON , Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

MedTech Insights report series analyzes the impact of recent breakthroughs in pulsed-field ablation, signaling its promising future in the electrophysiology mapping and ablation device market LONDON , Dec. 19, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the launch of a new special report series,  Electrophysiology Mapping and Ablation Devices Market Insights. The Clarivate MedTech Insights reports reveal new forecast predictions for the ablation catheter market in four geographies: the US, Europe, Japan and Asia Pacific.

Clarivate Reveals Stronger Outlook for Pulsed-field Ablation Market and Potential for Device to Revolutionize Treatment Paradigm

Clarivate has turned organic growth positive and has visible tailwinds that could drive organic growth higher. The company reported positive organic growth in 3Q23, beating consensus estimates for revenue and EBITDA margins. The A&G and LSH segments showed strong organic growth, and the IP segment is expected to recover as macro headwinds ease.

Clarivate: Rating Upgrade As Organic Growth Turns Positive

Informatica

Investors interested in stocks from the Internet - Software sector have probably already heard of Clarivate PLC (CLVT) and Informatica Inc. (INFA). But which of these two stocks is more attractive to value investors?

CLVT vs. INFA: Which Stock Is the Better Value Option?

New AI-enabled, integrated workflow provides pharma and biotech companies with comprehensive R&D insights to help minimize late-stage failures during clinical trials LONDON , Dec. 5, 2023 /PRNewswire/ --  Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the launch of VeriSIM Life Translational Index™ on Cortellis Drug Discovery Intelligence by Clarivate. The integrated workflow provides customers with a diverse array of predictive compound safety and efficacy insights, including bioavailability, hepatic and renal clearance, clinical toxicity, first-in-human dose and more.

News for Clarivate Plc Stock (CLVT)